SCHEMBL184577

SCHEMBL184577

O=S(=O)(Cl)c1ccc(Cl)c(Cl)c1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 2/20 0.40
MAPK1 P28482 2/20 0.39
CYP3A4 P08684 1/20 0.39
TSHR P16473 4/20 0.37
HPGD P15428 1/20 0.37
CASP1 P29466 1/20 0.37
HSD17B10 Q99714 1/20 0.37
DPP4 P27487 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CXCR2 P25025 4/20 0.33
HTT P42858 2/20 0.33
CXCR1 P25024 1/20 0.33
CX3CR1 P49238 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ALDH1A1 P00352 1/20 0.32
HSD11B1 P28845 1/20 0.31
GRIN2D O15399 1/20 0.31
GRIN3B O60391 1/20 0.31
GRIN1 Q05586 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL261900 0.83 MAPK1 (0.39) MAPK1CYP3A4TSHRHPGDCASP1
SCHEMBL6755511 0.81 MAPK1 (0.38) MAPK1CYP3A4TSHRHPGDCASP1
SCHEMBL10957618 0.81 CA1 (0.50) MAPK1CYP3A4TSHRCA1CA2
SCHEMBL31556483 0.79 TRPV4 (0.44) TRPV4MAPK1CYP3A4TSHRHSD17B10
SCHEMBL788147 0.79 TRPV4 (0.44) TRPV4MAPK1CYP3A4TSHRHSD17B10
SCHEMBL6755509 0.79 THRB (0.37) MAPK1CYP3A4TSHRHPGDCASP1
SCHEMBL4758230 0.79 TRPV4 (0.38) TRPV4TSHRHPGDHSD17B10DPP4
SCHEMBL10532523 0.78 TSHR (0.40) TRPV4MAPK1CYP3A4TSHRHPGD
SCHEMBL27812266 0.74 ACLY (0.42) TRPV4MAPK1TSHRCA1CA2
SCHEMBL8764082 0.74 TSHR (0.40) TRPV4MAPK1TSHRHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102112445-B Hydroxyphenylsulfonamides as antiapoptotic Bcl inhibitors BRISTOL MYERS SQUIBB CO 2014-06-18 CN disclosed
US-8501992-B2 Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-06 US disclosed
EP-2297103-B1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-01-04 EP disclosed
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-12-01 US disclosed
EP-2297103-A1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS Bristol-Myers Squibb Company (US) 2011-03-23 EP disclosed
WO-2009152082-A1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-17 WO disclosed
US-20070225344-A1 Sulfonamide derivatives to treat infection with hepatitis C virus WYETH 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225344-A1 Sulfonamide derivatives to treat infection with hepatitis C virus HCCS, HAVCR2, SULT2A1 TRPV4 2642/4885MAPK1 3511/4885CYP3A4 248/4885
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BCL2, BAX, BCL2A1 TRPV4 2846/4885MAPK1 1428/4885CYP3A4 3782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.